Arzneimittelwechselwirkungsstudie mit AZD5335 und Itraconazol bei Teilnehmerinnen mit Eierstock-, primärem Peritoneal- oder Eileiterkrebs
Eine offene, festgelegte Phasen-I-Studie zur Bewertung der Wirkung von Itraconazol (einem starken CYP3A-Inhibitor) auf die Pharmakokinetik von AZ14170132, der TOP1-Inhibitor-Nutzlast des Antikörper-Wirkstoff-Konjugats AZD5335, bei Teilnehmern mit Eierstock-, primärem Peritoneal- oder Eileiterkrebs
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a non-randomized, open-label, fixed sequence study to be conducted at multiple study centers.
The study will consist of 2 parts:
Part A of the study will comprise of:
- Screening period
- Treatment period: The treatment period will comprise of Cycles 1, 2 and 3 where the participants will receive AZD5335 along with itraconazole
- Follow-up visit (not applicable for participants involved in Part B)
Part B of the study will comprise of:
- Treatment period: Cycle 4 and onwards
- Safety Follow-up period
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-Mail: information.center@astrazeneca.com
Studienorte
-
-
-
Batumi, Georgia, 6010
- Zurückgezogen
- Research Site
-
Tbilisi, Georgia, 0114
- Zurückgezogen
- Research Site
-
Tbilisi, Georgia, 112
- Zurückgezogen
- Research Site
-
-
-
-
-
Dublin, Irland, D07 R2WY
- Rekrutierung
- Research Site
-
-
-
-
-
Lisbon, Portugal, 1250-068
- Rekrutierung
- Research Site
-
-
-
-
-
Barcelona, Spanien, 08023
- Rekrutierung
- Research Site
-
Logroño, Spanien, 26006
- Rekrutierung
- Research Site
-
Madrid, Spanien, 28040
- Rekrutierung
- Research Site
-
Madrid, Spanien, 28050
- Rekrutierung
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants with Platinum-resistant, relapsed, high- grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer and: (a) have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum; (b) must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion Criteria:
- Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Unresolved toxicities of Grade ≥ 2 (National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0) from prior therapy.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Uncontrolled intercurrent illness within 12 months prior to screening.
- Any other contraindication for receiving itraconazole according to the prescribing information and the Investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: AZD5335/AZD5335 + Itraconazole
In Part A, participants will receive AZD5335 alone as an intravenous (IV) infusion, and in combination with oral itraconazole, every 3 weeks (Q3W) from cycle 1 to cycle 3. In Part B, participants will receive AZD5335 as an IV infusion Q3W, from Day 1 of Cycle 4 until progression, unacceptable toxicity or any other specified criteria for discontinuation occurs. |
AZD5335 will be administered as IV infusion.
Andere Namen:
Itraconazole capsule will be administered orally. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the pharmacokinetics (PK) of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Maximum plasma drug concentration (Cmax)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the PK of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum plasma drug concentration (Cmax)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-17days of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Minimum plasma drug concentration (Cmin)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmin of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to the time of last measurable concentration (AUC0-t)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-t of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Terminal elimination (lambda_z)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
lambda_z of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Half life (t1/2)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
t1/2 of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Time to maximum observed concentration (tmax)
Zeitfenster: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
tmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Zeitfenster: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The safety and tolerability of AZD5335 alone and in combination with itraconazole will be assessed. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Objective response rate (ORR)
Zeitfenster: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR), with the denominator defined as the number of participants in the response evaluable set. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Duration of response (DoR)
Zeitfenster: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression). |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Progression-free Survival (PFS)
Zeitfenster: From Day 1 until until disease progression or death (up to 2 years)
|
The PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. |
From Day 1 until until disease progression or death (up to 2 years)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Genitalerkrankungen, weiblich
- Neoplasmen der endokrinen Drüse
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Eileitererkrankungen
- Eierstocktumoren
- Eileiterneoplasmen
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Azolen
- Triazoles
- Piperazines
- Itraconazol
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- D8991C00002
- EU CT (Andere Kennung: 2025-522731-34-00)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitment a made to the EFPIA PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .